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KRAS phosphorylation has been reported recently to modulate the activity of mutant 27 
KRAS protein in vitro. In this study, we defined S181 as a specific phosphorylation site 28 
required to license the oncogenic function of mutant KRAS in vivo. The phosphomutant 29 
S181A failed to induce tumors in mice, whereas the phosphomimetic mutant S181D 30 
exhibited an enhanced tumor formation capacity, compared to the wild-type KRAS 31 
protein. Reduced growth of tumors composed of cells expressing the non-32 
phosphorylatable KRAS S181A mutant was correlated with increased apoptosis. 33 
Conversely, increased growth of tumors composed of cells expressing the 34 
phosphomimetic KRAS S181D mutant was correlated with increased activation of AKT 35 
and ERK, two major downstream effectors of KRAS. Pharmacological treatment with 36 
PKC inhibitors impaired tumor growth associated with reduced levels of 37 
phosphorylated KRAS and reduced effector activation. In a panel of human tumor cell 38 
lines expressing various KRAS isoforms, we showed that KRAS phosphorylation was 39 
essential for survival and tumorigenic activity. Further, we identified phosphorylated 40 
KRAS in a panel of primary human pancreatic tumors. Taken together, our findings 41 
establish that KRAS requires S181 phosphorylation to manifest its oncogenic properties, 42 
implying that its inhibition represents a relevant target to attack KRAS-driven tumors. 43 
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Introduction  45 
RAS proteins are well-known small GTPases involved in the regulation of key signal 46 
transduction pathways. Cycling from the inactive (GDP-bound) to the active (GTP-47 
bound) state faithfully responds to extracellular signals due to its tight regulation by 48 
GTP-exchange factors (GEFs) and GTPase activating proteins (GAPs). Activating point 49 
mutations that render RAS proteins insensitive to the extracellular signals are crucial 50 
steps in the development of the vast majority of cancers (1-3). Three different genes 51 
code for a total of four different Ras isoforms named HRAS, NRAS, KRAS4A and 52 
KRAS4B. RAS mutations, mainly at the KRAS4B (herein after referred to as KRAS) 53 
genes, occur in pancreatic (95%), colon (40%) and adenocarcinomas of the lung (35%) 54 
(1, 4, 5). The most prevalent oncogenic mutations in RAS at codons 12, 13 and 61 55 
preserve the GTP-bound, active state by inhibiting intrinsic GTPase activity or 56 
interfering with the action of GAPs.  In the GTP-bound form, RAS is able to interact 57 
with different effector proteins and consequently activates signal transduction pathways. 58 
Among those, the best characterized are the RAF1/MEK/ERK and the 59 
phosphatidylinositol-3-kinase (PI3K)/AKT (6, 7).  60 
Since oncogenic mutations of KRAS give rise to an always GTP-bound protein which 61 
constitutively activates the effectors, positive or negative physiological regulation of 62 
oncogenic KRAS was not initially expected. Several reversible posttranslational 63 
modifications of KRAS have been described that could modulate KRAS oncogenic 64 
activity (8).  Ubiquitination of oncogenic KRAS at lysine-147 in the guanine 65 
nucleotide-binding motif increases its binding to the downstream effectors PI3K and 66 
RAF1 thus increasing its tumorigenic activity (9). Furthermore, acetylation at lysine-67 
104 affects interaction with GEFs and inhibits in vitro transforming activity of 68 
oncogenic KRAS (10). KRAS has, adjacent of the farnesylated C-terminal cysteine, a 69 
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stretch of six contiguous lysines in a total of eight lysine residues -known as the 70 
polybasic domain- which promotes an electrostatic interaction with the negatively-71 
charged phosphate groups of phospholipids (11, 12). Phosphorylation of KRAS at 72 
serine-181 within this domain has been described (13). We previously reported a role of 73 
KRAS Ser181 phosphorylation for activation of the wild-type KRAS in vitro and to 74 
regulate also in vitro oncogenic KRAS activity (14).  By using both a genetic and 75 
pharmacological approach we demonstrate here that phosphorylation of oncogenic 76 
KRAS is required for tumor growth in vivo and that also this modification can be 77 
detected in human tumors. Furthermore, pharmacological inhibition of oncogenic 78 
KRAS phosphorylation suppresses KRAS oncogenic activity.  79 
 80 
Materials and Methods 81 
Antibodies and reagents 82 
Primary antibodies used for immunoblotting were as follow: Anti-Actin (clone C4) 83 
(#691001; 1:1000; MP Biomedicals, Santa Ana, CA, USA), Anti-GAPDH (#MAB374; 84 
1:1000; Chemicon, Billerica, MA, USA); Anti-cleaved caspase-3 (Asp175) (#9661;  85 
1:1000; Cell Signaling, Danvers, MA, USA); Anti-AKT (#9272; Cell Signaling); Anti-86 
phospho-AKT (Thr308) (#9275; 1:1000, Cell Signaling), Anti-p44/42 MAPK (ERK 87 
1/2) (#9102; 1:1000; Cell Signaling); Anti-phospho-p44/42 MAPK (ERK 1/2) 88 
(Thr202/Tyr204) (#9101; 1:1000; Cell Signaling), Anti-cyclin B1 (#4138; 1:1000; Cell 89 
Signaling); Anti-KRAS (clone Ab-1) mouse (#OP24, 1:400, Calbiochem); Anti-Pan-90 
Ras (clone Ab-3) mouse (#OP40; 1:400; Calbiochem); Anti-HRAS (clone C20) rabbit 91 
(#Sc-520, Santa Cruz); Anti-NRAS (clone F155) mouse (#Sc-31, Santa Cruz); Anti-92 
GAP120 (sc-63; 1:100; Santa Cruz, Santa Cruz, CA, USA); Anti-PKC (#610398; 93 
1:500; BD Transduction Laboratories, San Jose, CA); Anti-phospho-PKC 94 
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(Ser643/676) (#9376; 1:1000; Cell Signaling). For immuhistochemistry we used Anti-95 
Ki-67 (SP6) (#NM-9106S; 1:200; NeoMarkers, Kalamazoo, MI, USA). We used 96 
DeadEnd Colorimetric TUNEL System (G7132; Promega) for the TUNEL assays. 97 
The reagents used for the detection of phospho-KRAS were: Protein Phosphatase  98 
(#539514-20KV; Calbiochem); Phos-tag™ (#AAL-107, Wako Chemicals GmbH, 99 
Neuss, Germany).  100 
The inhibitors of PKC used were: Bryostatin-1 (#BIB0342, Apollo Scientific, Chesire, 101 
UK), Edelfosine (1-O-Octadecyl-2-O-methyl-glycero-3-phosphorylcholine) (#BML-102 
L108, Enzo Life Science, Farmingdale, NY, USA), Bisindolylmaleimide I (BIM) 103 
(#CAS 176504-36, Millipore), Gö6983 (#G1918, Sigma Aldrich).  104 
 105 
Cell lines 106 
NIH3T3, SW480, A549, MPanc-96 and HPAF-II cells obtained from American Tissue 107 
and Cell Collection (ATCC) were grown in Dulbecco’s Modified Eagle’s Medium 108 
(DMEM) containing 10% FCS (Biological Industries), and routinely verified according 109 
to the specifications outlined in the ATCC Technical Bulletin. NIH3T3 stable cell lines 110 
expressing either HA-KRASG12V, HA-KRASG12V-S181A or HA-KRASG12V-111 
S181D were obtained as previously described (14) . 112 
DLD-1 knock-out of mutant KRAS allele DLD1KRASwt/-  were obtained from Horizon 113 
Discovery Ltd (clone D-WT7; #HD105-002; http://www.horizondiscovery.com; 114 
Cambridge, UK). DLD1KRASwt/- cells were generated using the proprietary adeno-115 
associated virus (AAV) gene targeting technology GENESIS®. Cells were maintained 116 
according to the supplier recommendations in McCoy’s modified media containing 10% 117 
FBS (Biological Industries). DLD1KRASwt/- stable cell lines expressing either HA-118 
KRASG12V, HA-KRASG12V-S181A or HA-KRASG12V-S181D were obtained from 119 
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DLD1KRASwt/- after transfecting with the specific HA-KRASV12 plasmids (14)  and a 120 
puromycine resistance plasmid (pSG5A). After selection with puromycine (4 μg/mL) 121 
clones or pools were obtained.  .  122 
 123 
Tumor generation in mice 124 
The day of the injection, one million NIH 3T3 cells stably expressing either HA-125 
KRASG12V, HA-KRASG12V-S181A or HA-KRASG12V-S181D suspended in 0,1 126 
mL PBS buffer were subcutaneously injected into both flanks of Swiss nude mice 127 
(foxn1-/-). Generated tumors were measured over time and at day 18 after injection, 128 
mice were euthanized and tumors were harvested, weighed, measured and processed for 129 
analysis (each group n=10). 130 
For DLD-1 xenografts, one million cells stably expressing either HA-KRASG12V or 131 
HA-KRASG12V-S181A suspended in 0,1 mL PBS buffer were subcutaneously injected 132 
into both flanks of Swiss nude mice (foxn1-/-). Generated tumors were measured over 133 
time and at day 28 after injection, mice were euthanized and tumors were harvested, 134 
weighed, measured  and processed for analysis (each group n=10). 135 
For the assays with the PKC inhibitors, one million NIH 3T3 cells stably expressing 136 
either HA-KRASG12V or HA-KRASG12V-S181D were subcutaneously injected into 137 
both flanks of Swiss nude mice. When tumor reached a designated volume of ~150 mm3, 138 
animals were randomized and divided into vehicle (DMSO), Bryostatin-1 or Edelfosine 139 
treatment groups. Mice were weighed daily and received an intraperitoneal injection of 140 
either 75 μg/Kg Bryostatin-1 in 5% (v/v) DMSO, 30 mg/Kg Edelfosine in 5% (v/v) 141 
DMSO or 5% (v/v) DMSO (vehicle) for 5 days. At day 6 after the beginning of the 142 
treatment, mice were euthanized and tumors were harvested, weighed and processed for 143 
analysis. 144 
Research. 
on January 7, 2014. © 2013 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 26, 2013; DOI: 10.1158/0008-5472.CAN-13-1750 
7 
 
All mouse experiments were performed in accordance with protocols approved by the 145 
Animal Care and Use Committee of ICO-IDIBELL Hospitalet de Llobregat, Barcelona, 146 
Spain.    147 
 148 
Sample Lysis, Gel electrophoresis, immunoblotting, 149 
Cultured cells were lysed in Ras extraction buffer (20 mM Tris–HCl, pH 7.5, 2 mM 150 
EDTA, 100 mM NaCl, 5 mM MgCl2, 1% (v/v) Triton X-100, 5 mM NaF, 10% (v/v) 151 
glycerol and 0.5% (v/v) 2-mercaptoethanol) supplemented with a cocktail of protease 152 
and phosphatase inhibitors (0.1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, 10 153 
mM -glycerophosphate, 2 g/ml aprotinin and 10 g/ml leupeptin) 154 
Tumors were lysed using Polytron (Fischer Scientific, Pittsburg, PA, USA) in Ras 155 
extraction buffer, and protein resolved using standard SDS-PAGE electrophoresis. After 156 
electrotransfer, membranes were incubated using the indicated antibodies and then 157 
incubated with peroxidase-coupled secondary antibody. Immunocomplexes were 158 
detected by enhanced chemiluminescence reaction ECL western blotting analysis 159 
system (Amersham Biosciences, Piscataway, NJ, USA) and imaged by LAS-3000 160 
(Fujifilm, Tokyo, Japan). When required, band intensity was determined using the 161 
measurement tool of Multigauge 2.0 (FUJIFILM, Tokyo, Japan). 162 
 163 
Cell viability assay (MTT) 164 
Human cell lines or DLD-1 expressing the same amounts of HA-KRASG12V and HA-165 
KRASG12V-S181D were seeded at 104 cells per p96 with DMEM 10% FCS. Next day, 166 
were treated with the corresponding concentration of PKC inhibitors for 48h. Then, 10 167 
μL of AB solution (MTT Cell Growth Assay Kit, #CT02, Millipore) were added to each 168 
well and incubated at 37ºC for 4h. Then, 0.1 mL isopropanol with 0.04 N HCl was 169 
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added and mixed thoroughly. Absorbance was measured with a test wavelength of 570 170 
nm and a reference wavelength of 630 nm according to manufacturer’s 171 
recommendations. 172 
 173 
Measurement of Ras isoform activation 174 
RBD (Ras-binding domain of Raf-1) pull-down assays were performed as previously 175 
described (14)  to determine the amount of active K-, H- and NRAS. 176 
 177 
Histology  178 
Mice tumors were embedded either in paraffin or frozen in OCT. Paraffin sections were 179 
stained following the haematoxylin-eosin standard protocol to study their histological 180 
appearance. Mitotic count in 5 consecutive high-power fields (100x) was performed to 181 
compare the mitotic index between groups.  Frozen section in OCT were used to 182 
determine apoptosis by TUNEL assay following manufacturers recommendations 183 
(Roche), and to determine the percentage of proliferating cells by  184 
immunohistochemistry  using Ki-67  antibodies.    185 
 186 
Human tumors 187 
Five biopsies of Human Pancreatic Ductal Adenorcarcinoma obtained by 188 
Doudenopancreatectomy were orthotopically implanted to nude mice and were 189 
perpetuated at least four passages.  All patients gave informed written consent to 190 
participate and to have their biological specimens analyzed. The study was cleared by 191 
the Ethical Committee of Hospital de Bellvitge. 192 
 193 
Detection of phospho-KRAS  194 
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Phos-tagTM SDS-PAGE. To detect phospho-KRAS from human tumor samples and 195 
from nude mice grafts, a fragment of ~ 0,1 g from a tumor biopsy was homogenized in 196 
0,4 mL of  Phosphatase Lysis Buffer (50 mM Tris-HCl pH 8; 150 mM NaCl, 2 mM 197 
EDTA, 10% Glycerol, 1% Nonidet P40, 5 mM DTT, 2mM  MnCl2) containing either 198 
protease inhibitor cocktail (Halt Protease Inhibitor Cocktail, #87786, Thermo Scientific, 199 
Rockford, IL USA) alone or plus phosphatase inhibitors (0.2 mM Na3VO4, 5 mM NaF). 200 
For human cell lines, a 10 cm dish was homogenized in the  Phosphatase Lysis Buffer 201 
as described above. Then, samples homogenized with only protease inhibitors were 202 
treated with recombinant Protein Phosphatase  for 30 minutes at 30ºC according to 203 
manufacturer instructions, and finally all tubes were balanced with phosphatase 204 
inhibitors in order to equalize both lysis buffers. 205 
Protein content was assessed by Lowry method (Lowry et al, 1951) and tubes were 206 
balanced. 10 μg protein were loaded into a 12%-polyacrilamide SDS-PAGE gel 207 
supplemented with 100 μM Phos-tagTM and 100 μM MnCl2 (according to Phos-tagTM 208 
SDS-PAGE protocol indicated by manufacters). The gel was run over night at 5 mA/gel 209 
and soaked in a general transfer buffer containing 1 mM EDTA for 20 min followed by 210 
10 minutes incubation with a transfer buffer without EDTA. Then, gels were transferred 211 
over night at 50 V into a PDVF membrane that was blocked and blotted with anti-212 
KRAS (#OP24, Calbiochem). 213 
Two-dimensional gel electrophoresis (2-DE). 100 g of tumor extract prepared as 214 
indicated above, were diluted to a final concentration of 7M urea, 2M thiourea, 4% 215 
CHAPS {3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate}, 65 mM 216 
DTE, 0.1% ampholytes (Bio-Lyte 3/10, no. 163-1113; Bio-Rad) and 1.2% DestreakTM 217 
Reagent (GE Healthcare, 17-6003-18) to 125 L volume. Two-dimensional first-218 
dimension electrophoresis was performed as isoelectric focusing (IEF) with precast, 219 
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immobilized pH gradient (IPG) gel strips (ReadyStripTM IPG Strip, 7 cm, pH 7 to 10; 220 
no. 163-2005 [Bio-Rad]) by using a PROTEAN IEF system (Bio-Rad). Sample 221 
application and rehydration of the strips were carried out using the active method (50 V 222 
contant) according to the manufacturer's instructions (Bio-Rad). Next focusing was 223 
performed at 8000 to 20000 V per hour. IEF gels were equilibrated for 10 min in a 224 
buffer containing 6 M urea, 0.375 M Tris [pH 8.8], 2% SDS, 20% glycerol, and 2% 225 
[wt/vol] DTE, and the second-dimension run was carried out in SDS-polyacrylamide 226 
gels. After electrophoresis, gels were transferred to PDVF membranes (Millipore) and 227 
immunoblotted with antibodies against KRAS 228 
 229 
Statistics 230 
All analyses were performed with GraphPad Prism 5.0.  Data represent mean ± SEM. 231 
Mann-Whitney test was used to analyze significance levels. Specific significance levels 232 
are found in figure legends. P < 0.05 was considered significant. 233 
  234 
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Results and Discussion 236 
Oncogenic KRAS phosphorylation at Ser-181 is required for tumor growth 237 
To test the prediction that phosphorylation at Ser181 of oncogenic KRAS was required 238 
to support tumor growth, NIH3T3 stable cell lines expressing similar levels of 239 
oncogenic HA-tagged G12V KRAS, namely HA-KRAS-G12V-S181 (S181), non-240 
phosphorylatable HA-KRAS-G12V-S181A (S181A) or phosphomimetic HA-KRAS-241 
G12V-S181D (S181D) (Fig. 1A) were subcutaneously injected into nude mice and 242 
tumor growth was monitored over time. Tumor formation was nearly abolished in cells 243 
expressing non-phosphorylatable S181A (Fig. 1B,C and tables S1 and S2). Furthermore, 244 
a dramatic increase in tumor growth was observed for phosphomimetic S181D mutant 245 
compared to the phosphorylatable S181. No tumor growth was observed when injecting 246 
NIH3T3 cells stably expressing wild-type HA-KRAS (Table S1), which confirmed that 247 
both engraftment and growth was driven by our oncogenic KRAS phosphomutants. 248 
Interestingly, in spite of the dramatic diminished growth of non phosphorylatable 249 
S181A derived tumors, KRAS oncoprotein was overexpressed in those tumors 250 
compared to the S181 or S181D derived tumors (Fig. 1D). This suggests that, during the 251 
process of tumor development, cells with higher expression of non-phosphorylatable 252 
KRAS are positively selected in an attempt to overcome the lower tumorogenic activity 253 
exhibited by this mutant.  Similar results were obtained when injecting in nude mice 254 
two independently immortalized S181A clones with distinct expression levels. Again in 255 
S181A clones, tumor growth was highly compromised irrespectively of the KRAS 256 
protein expression level (Fig. S1).  257 
The impaired tumor growth of the non-phosphorylatable S181 G12V mutant associated 258 
with a distinct histological pattern. S181A tumors were composed mostly by cells with 259 
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an epithelioid appearance and with a significant lymphocytic infiltration (S181A 10.00 260 
± 1.08 lymphocytes per x100 field vs S181 2.25 ± 0.63 vs S181D 1.25 ± 0.25, 261 
p<0.0001) (Fig. 3 and Fig.S3). Of note, the same histology has been previously reported 262 
for sarcomas harboring the mild KRAS codon 13 mutations (15).  In contrast, S181 and 263 
S181D derived sarcomas were composed of a fusocellular population showing a 264 
hemangiopericitoid patterns. The non-phosphorylatable S181A tumors had also a lower 265 
mitotic rate (S181A 4.00 ± 1.53 mitotic cells per x100 field vs  27.00 ± 4.12 for S181 vs  266 
54.75 ± 4.99 for S181D, p<0.0001) and were the only tumors  showing  detectable 267 
levels of cleaved-caspase 3, a bona fide apoptosis marker (Fig. 1D and Fig S2A), 268 
together with a significant increase in TUNEL positive cells (Fig. 2A, B.). This is in 269 
accordance with the decreased resistance to apoptosis already reported in vitro for 270 
S181A compared to S181 and S181D oncogenic KRAS mutants (14). In agreement with 271 
the prediction of a stronger activity of KRAS upon phosphorylation, the 272 
phosphomimetic S181D derived tumors exhibited higher ERK and AKT activity (Fig. 273 
1D), accompanied by a pronounced increase in the number of positive cells for the 274 
proliferative marker Ki-67 (Fig. 2A,B). Although mild increase in TUNEL positive 275 
cells was also observed in S181D compared to S181 tumors, S181A tumors were the 276 
ones exhibiting the highest degree of apoptosis. Intriguingly, S181A tumors showed 277 
higher cyclin B1 expression than the others (Fig. 1D) in line with the requirement of 278 
increased Cyclin B1 for apoptosis induction previously reported in several tumor cell 279 
lines (16-18). Moreover, Cyclin B1 overexpression has already been related to the mild 280 
transforming phenotype of codon 13 KRAS mutations in NIH3T3 models (15).  281 
Thus, the impossibility of phosphorylating oncogenic KRAS dramatically changes 282 
growth pattern rendering activating mutations much less aggressive and demonstrating 283 
the relevance of this posttranslational modification in KRAS-driven transformation. 284 
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PKC inhibitors diminish oncogenic KRAS-mediated tumor growth  286 
The dependence of oncogenic KRAS on S181 phosphorylation makes oncogenic KRAS 287 
a putative target for protein kinase inhibitors.  Since PKCs are considered to be the 288 
putative kinases for KRAS Ser181 phosphorylation (13, 19, 20) we tested whether 289 
treatment with two general PKC inhibitors that are clinically relevant (Bryostatin-1 and 290 
Edelfosine) (21-25) were able to revert tumor growth in a dephosphorylation-dependent 291 
manner.  292 
Bryostatin-1 inhibits PKC activity when administrated in vitro at concentrations as low 293 
as 0.1 nM (21). In our experiments we used 75 μg/Kg, a dose that was previously used 294 
for in vivo PKC inhibition (26). As shown in Fig. 4B, Bryostatin-1 treatment 295 
significantly reduced tumor growth of S181 whereas no effect was evident on “non-296 
dephosphorylatable” S181D tumors. Of note, we found that Bryostatin-1 treatment, in 297 
accordance to its general PKC inhibitor activity, efficiently downregulated both total 298 
and active PKC levels as previously described (21) (Fig. 4C). Tumor reduction with 299 
Bryostatin-1 treatment was associated with a decreased ERK activity that was specific 300 
for S181 phosphorylatable mutant. Moreover, apoptosis was induced as shown by an 301 
increase of cleaved caspase-3 levels and TUNEL positive cells (Fig. 4C,D and Fig. 302 
S2B). Concomitantly, cell proliferation was inhibited (Fig. 4D.) while cyclin B1 303 
expression was increased (Fig. 4C). In this way, Bryostatin-1 treatment showed high 304 
specificity for the dephosphorylatable S181 tumors and interestingly, treatment of these 305 
tumors efficiently recapitulated the growth and signaling pattern of S181A tumors 306 
(21)shown in Fig.1. Concordantly, PKC inhibition did not affect growing and signaling 307 
pattern, nor increased apoptosis in the non-dephosphorylatable KRAS S181D tumors. 308 
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To further confirm the striking results obtained with Bryostatin-1 treatment on mice we 309 
treated the same stable transfected NIH3T3 mice grafts with Edelfosine. This is an ether 310 
lipid analog to HMG with reported strong PKC inhibitor activity both in vitro (27, 28) 311 
and in vivo (29). As shown in Fig S4, we reproduced a significantly reduced tumor 312 
growth of S181 and again no significant effect was observed in “non-313 
dephosphorylatable” S181D tumors.  314 
Altogether, these results suggested that both Bryostatin-1 and Edelfosine, by blocking 315 
PCK activity, impair tumor growth inducing KRAS dephosphorylation and subsequent 316 
apoptosis. To formally prove this hypothesis, detection of KRAS phosphorylation was 317 
necessary.  Since no suitable antibodies are available, we used the Phos-TagTM-based 318 
approach (30, 31) to determine the oncogenic KRAS phosphorylation status in the 319 
generated tumors. This method is based on the fact that a complex formation between 320 
the phosphate group of a phosphorylated protein and a divalent metal ion in Phos-Tag™ 321 
reduces the mobility of the phospho-protein during the electrophoresis separation, thus 322 
allowing resolution of phosphorylated and non-phosphorylated proteins into different 323 
bands. As shown in Fig. 4E, a slow migrating band of HA-KRAS could be observed in 324 
the tumors generated from cells expressing the S181 oncogenic KRAS, that was absent 325 
in S181D tumors. Disappearance of this band upon λ Phosphatase treatment 326 
corroborated it was phosphorylated KRAS. Most interestingly, in Bryostatin-1 and 327 
Edelfosine treated animals phosphorylated KRAS was no longer observed (Fig.4E and 328 
Fig.S4).  Together, these observations reinforce the notion that PKC-dependent Ser181-329 
phosphorylation of oncogenic KRAS is required for tumorigenesis. This effect may 330 
account for the previously reported inhibition of different KRAS-driven tumor 331 
xenografts by PKC pharmacologic inhibition (29, 32, 33). Interestingly, it has also been 332 
Research. 
on January 7, 2014. © 2013 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 26, 2013; DOI: 10.1158/0008-5472.CAN-13-1750 
15 
 
shown that PKCδ knock-down prevents apoptosis and promotes tumorigenesis in cells 333 
addicted to aberrant KRAS signaling (34-36).  334 
 335 
Human cell lines require phosphorylation of KRAS for survival and tumor growth 336 
In order to determine whether the requirement for KRAS phosphorylation observed in 337 
our NIH3T3 KRAS-transformation model was also involved in human cell lines 338 
tumorigenesis, we ectopically expressed the HA-KRAS-G12V phosphomutants 339 
described above in the human colorectal cancer cell line DLD-1 but previously 340 
knocked-out for the oncogenic endogenous KRAS allele (DLD1KRASwt/-).  341 
We found that under serum-saturating growth conditions (10%FCS), human colon 342 
cancer cells DLD-1 expressing S181A mutant exhibited a significantly reduced growth 343 
compared to phosphomimetic S181D expressing cells (Fig. 5A). Trying to recapitulate 344 
tumor growth conditions, we evaluated cell growth under serum-limiting conditions 345 
(0.1% FCS). After 4 days of starvation, cells stably expressing S181A showed 346 
significantly higher reduced growth under serum starvation culture conditions compared 347 
to S181 and phosphomimetic S181D (Fig. 5A,). Moreover, S181A exhibited increased 348 
sensitivity to apoptosis under serum deprivation or by adriamycin- induced genotoxic 349 
damage (Fig 5A,B), thus demonstrating a pro-apoptotic effect of the S181A oncogenic 350 
KRAS. 351 
In order to evaluate real tumorigenic capacity of these cells, subcutaneous injection of 352 
DLD1KRASwt/- expressing either HA-KRASG12V or HA-KRASG12V-S181A 353 
phosphomutants was performed. S181A derived tumors were significantly smaller than 354 
S181 tumors (Fig. 5C). This confirmed the requirement of KRAS S181 phosphorylation 355 
for tumorigenesis of human colon cell lines. 356 
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A preferential activation of endogenous wild-type H- and N- RAS alleles induced by the 357 
oncogenic KRAS has recently been reported (37). To check whether diminished growth 358 
capacity of S181A was due to lack of activation of the endogenous RAS isoforms,  359 
RBD pull-down assays were performed to test GTP loading of endogenous RAS 360 
isoforms. Lower GTP loading of endogenous Ras in the S181A expressing cells was not 361 
observed compared with the other phosphomutants  (Fig. S5).  362 
Next, we wanted to determine whether BIM and Gö6983, two PKC inhibitors (38, 39)  363 
were able to affect DLD-1 cells in a KRAS S181-specific manner. To this aim, dose-364 
response to these PKC inhibitors was evaluated in DLD1KRASwt/- cells expressing HA-365 
KRASG12V and using DLD-1 expressing HA-KRASG12V-S181D as a non-366 
dephosphorylatable control. After 48h of treatment, it was shown that at doses between 367 
1μM and 20μM for BIM and 1.5μM and 10μM for Gö6983, cells expressing oncogenic 368 
KRAS with S181 exhibited significantly enhanced sensitivity to PKC inhibition 369 
compared to the phosphomimetic non-dephosphorylatable mutant (Fig 6A). Most 370 
importantly, after PKC inhibition, S181 cells lost its KRAS phosphorylation as shown 371 
by Phos-tagTM SDS-PAGE gels (Fig 6A). 372 
Finally, we evaluated the ability of a set of PKC inhibitors to reduce proliferation 373 
together with KRAS phosphorylation in a panel of human cell lines from different 374 
origin harboring oncogenic KRAS. We found that at doses reported to inhibit PKC (21, 375 
28, 38, 40), cell growth was compromised. Most importantly, after 12h of treatment, 376 
band corresponding to phospho-KRAS was lost, thus reinforcing the idea that PKC 377 
inhibition is able to revert growth in a KRAS S181-dependent manner (Fig. 6B). 378 
 379 
KRAS is phosphorylated in human tumors. 380 
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Next, we investigated whether the S181 phosphorylation observed in our model system 381 
was also present in human tumors. To do so, a set of orthotopic xenografts derived from 382 
carcinomas of the exocrine pancreas were analyzed. Five tumors harboring codon 12 383 
KRAS mutations were tested. As shown in Fig. 7, by using Phos-TagTM SDS-PAGE, 384 
several bands were detected in all tumors using the anti-KRAS antibody. Treatment 385 
with  phosphatase (Fig. 7) and two-dimensional electrophoresis analysis corroborated 386 
the presence of phosphorylated KRAS in these human tumors (Fig. S6). Thus, the 387 
presence of phospho-KRAS in human malignancies emphasizes the alleged requirement 388 
of this modification for human KRAS-driven tumorigenesis. 389 
Altogether, the results depict a scenario of a novel tight regulation of KRAS 390 
oncogenicity by phosphorylation at S181.  We have recently shown that although 391 
phosphorylated KRAS is mainly found at the plasma membrane (40, 41), 392 
phosphorylated K-Ras forms distinct plasma membrane signaling platforms that induce 393 
preferential activation of main KRAS effectors involved in oncogenesis . Interestingly, 394 
this distinct functionality could be reverted by PKC inhibitors (40).   This would give a 395 
rationale for the strikingly different tumorigenic activity of oncogenic KRAS  according 396 
to its S181 phosphorylation status .   397 
The fact that, as we show, this could be efficiently pharmacologically inhibited raises 398 
the possibility of novel therapeutic strategies targeting KRAS-driven human 399 
malignancies.  So far, clinical trials with PKC regulators have been disappointing 400 
mostly because of the lack of selectivity and unacceptable toxicity (39). The 401 
identification of KRAS as a key PKC target may help in developing specific inhibitors 402 
of KRAS phosphorylation. 403 
  404 
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Figure Legends 521 
Fig. 1. Phosphorylation at Ser181 is necessary for tumor growth of oncogenic 522 
KRAS-G12V. NIH 3T3 cells stably expressing either, HA-KRAS-G12V (S181), HA-523 
KRAS-G12V-S181A (S181A) or HA-KRAS-G12V-S181D (S181D) were injected into 524 
each flank of nude mice (each group n=10). A) Levels of exogenous HA-KRAS from 525 
the different NIH 3T3 pools were analyzed by immunoblot the day of injection into 526 
mice. Pool S181#2 was injected into mice (herein after referred to as S181); B) Tumor 527 
volumes were measured at days 13, 16 and 19 after injection; C) At day 19 mice were 528 
euthanized and tumors were dissected and weighed. Graph showing the weight of 529 
excised tumors (each dot corresponds to a tumor); D) Total cell lysates of representative 530 
excised tumors were immunoblotted to detect the indicated proteins (numbers indicate 531 
different tumors). Anti-GAP120 was used as loading control;  532 
Fig. 2. Lack of growth of non-phospohorylatable KRAS tumors correlates with 533 
decreased proliferation (Ki-67) and increased apoptosis (TUNEL) markers. A) 534 
Tumor sections were stained for Ki-67 or TUNEL. Scale bars represent 50 μm;B) 535 
Quantifications of Ki-67 labeling (left) and TUNEL labeling (right) were made from at 536 
least 2 different tumors per mutant (each point represents a counted field).  (***, 537 
p<0.0001, **, p<0.001 and *, p<0.01, p for Student’s two-tailed t test; mean and SEM 538 
are represented).  539 
Fig. 3. Differential tumor growth according to KRAS phosphorylation is associated 540 
with a distinct histological patern. Paraffin sections were stained following the 541 
haematoxylin-eosin protocol to study their histological appearance. Arrow caps indicate 542 
lymphocyte infiltration. Scale bars represent 50 μm.  543 
Fig. 4. Pharmacologic inhibition of PKC activity inhibits tumor growth and 544 
KRAS-G12V dependent signaling pathways in a K-RasG12V Ser181-545 
phosphorylation dependent manner. NIH 3T3 cells stably expressing either HA-546 
KRAS-G12V (S181); or HA-KRAS-G12V-S181D (S181D) were injected into each 547 
flank of nude mice. When tumor reached a designated volume of ~150 mm3 (latency 548 
time shorter for S181D tumors), animals were divided into two groups (each group 549 
n=10) and treated daily either with vehicle (5% DMSO) or Bryostatin-1 (Bryo) (75 550 
μg/Kg) for 6 days, and euthanized next day. A) Western blot showing HA-K-Ras 551 
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expression in different pools of NIH 3T3 cells the day of injection. Injected NIH 3T3 552 
pools (red arrows) were chosen among the ones with equivalent expression for HA-553 
KRAS-G12V (S181) or HA-KRAS-G12V-S181D (S181D); B) Increment in tumor size 554 
was obtained by comparing tumor volume at the starting day (day 1) and at day 7 of 555 
treatment. Dissected tumors from the nude mice are displayed below the graph. Scale 556 
bar represents 25 mm C) Total cell lysates of representative excised tumors were 557 
immunoblotted to detect the indicated proteins (numbers indicate different tumors). 558 
Anti-GAP120 was used as loading control D) Quantifications of Ki-67 labeling (left) 559 
and TUNEL labeling (right) were made from at least 2 different tumors per mutant 560 
(each point represents a counted field).  (***, p<0.0001, **, p<0.001 and *, p<0.01, p 561 
value for Student’s two-tailed t test; ns: non-significant differences; mean and SEM are 562 
represented). E) Cellular extract from tumors were resolved in Phos-TagTM SDS-PAGE 563 
gels and immunoblot was performed using anti-HA antibody. An aliquot of a S181 564 
tumor from an animal treated with DMSO was incubated, prior to electrophoresis, at 565 
30ºC with phosphatase  () or only with buffer (Ctl) to discard unspecific effects due to 566 
heating samples. 567 
Fig. 5. Phosphorylation at Ser181 is necessary for cell proliferation, survival and 568 
tumor growth of DLD1 KRAS wt/- cell expressing KRASG12V phosphomutants. A) 569 
3·104 DLD1 KRAS wt/- cells stably expressing either HA-KRASG12V-S181A, HA-570 
KRASG12V-S181D or HA-KRASG12V-S181 were cultured under serum-saturated 571 
(10% FCS) or serum-limiting (0.1% FCS) conditions for 4 days and counted to evaluate 572 
the proliferation rate. KRAS expression of the different mutants at the initial day and 573 
levels of cleaved caspase 3 (Cl. casp 3) at the fourth day are showed. B) The different 574 
mutants were cultured for 2 days with adryamicin (5μM) to induce genotoxic damage. 575 
The sensitivity to apoptosis was analyzed by the levels of cleaved caspase 3 (Cl. casp 576 
3). C)  Pools of DLD1 KRAS wt/- expressing HA-KRAS-G12V S181 or HA-KRAS-G12V 577 
S181A were injected into each flank of nude mice. Levels of exogenous HA-KRAS 578 
from the pools injected were analyzed by immunoblot the day of injection into mice. At 579 
day 28 after injection mice were euthanized and tumors were weighed. Graph showing 580 
the weight of excised tumors.  581 
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Fig.6. Pharmacologic PKC inhibition impairs KRAS phosphorylation and cell 583 
survival. A) DLD1 KRAS wt/-  expressing KRASG12V -S181  or KRASG12V-S181D (as 584 
non-dephosphorylatable control)  were treated with the PKC inhibitors Gö6938 (Gö) 585 
(1.5, 5 and 10 μM)  and BIM (1, 10 and 20  μM) for 48 hours.  The columns represent 586 
the growth rate estimated by the measurement of the absorbance following the MTT 587 
assay as a function of the initial cell number (left). Extracts from DLD1 KRAS wt/-  588 
expressing KRASG12V -S181  or KRASG12V-S181D treated or no with phosphatase  589 
() or with PKC inhibitors (Gö6983 or BIM) were resolved in Phos-TagTM SDS-PAGE 590 
gel following by immunoblotting using anti-KRAS antibodies (right).B) A pannel of 591 
human cell lines from different origin harboring oncogenic KRAS were treated with 5 592 
μM BIM, 1 μM Gö6983 (Gö), 1 μM Bryostatin-1(Bryo) and 10 μg/mL Edelfosine 593 
(Edelf) for 48h. Cells were harvested and extracts were resolved in Phos-TagTM SDS-594 
PAGE and immunoblotted using anti-KRAS antibody. 595 
Fig. 7. Detection of the phosphorylated form of oncogenic KRAS in human 596 
pancreatic ductal adenocarcinomas.  Extract from 5 different human pancreatic ductal 597 
adenocarcinomas with oncogenic mutations in codon 12 of KRAS (#1 G12D 598 
heterozygous; #2 G12D heterozygous; #3 G12D homozygous; #4 G12V heterozygous; 599 
#5 G12V heterozygous), were resolved in Phos-TagTM SDS-PAGE or SDS-PAGE 600 
followed by immunoblotting using anti-KRAS antibodies. An aliquot of each extract 601 
was previously incubated with phosphatase . Anti-GAP120 was used as loading 602 
control. 603 
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